Maze Insider Reports $736K Sale. Here’s What Investors Should Know as Stock Plunges 33%
This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.
Other News
Core & Main: Fiscal Q4 Earnings Snapshot
Cintas (CTAS) Reports Earnings Tomorrow: What To Expect
Why Viking Therapeutics Stock Could Take Off Later This Year
Arbutus: Q4 Earnings Snapshot
Where Will FMC Stock Be in 1 Year?
Investor Reveals $51 Million Sale of Armstrong Strong as Shares Sink Post-Earnings
Top 3 Energy Dividend Stocks for Reliable Income in 2026
Rumble (RUM) Q4 2025 Earnings Call Transcript